Ronald Kirk Huntsman - 26 Nov 2024 Form 4 Insider Report for Vivos Therapeutics, Inc. (VVOS)

Role: Chief Executive Officer, Director
Signature: /s/ Bradford K. Amman as attorney-in-fact for Ronald Kirk Huntsman
Issuer symbol: VVOS
Transactions as of: 26 Nov 2024
Net transactions value: +$832,711
Form type: 4
Filing time: 27 Nov 2024, 16:47:13 UTC
Previous filing: 28 Jun 2024
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
holding	VVOS	Common Stock						3,461	26 Nov 2024	Direct
holding	VVOS	Common Stock						69,600	26 Nov 2024	See footnote	F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	VVOS	Stock Option (Right to Buy)	Award	$832,711	+315,421	+639%	$2.64	364,755	26 Nov 2024	Common Stock	315,421	$2.64	Direct	F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Shares held by Coronado V Partners, LLC, of which the Reporting Person is a member and manager.
F2	On September 7, 2024 (the "Grant Date"), the Reporting Person received a grant of 315,421 stock options, which grant was made under but subject to stockholder approval of the Issuer's 2024 Omnibus Equity Incentive Plan and such grant at the Issuer's 2024 Annual Meeting. Such meeting was held, and such stockholder approval was obtained, on November 26, 2024. One-third shall vest and become exercisable in three installments on each of the first, second and third anniversaries of the date of grant through September 7, 2027.

Content

Shares held by Coronado V Partners, LLC, of which the Reporting Person is a member and manager.

On September 7, 2024 (the "Grant Date"), the Reporting Person received a grant of 315,421 stock options, which grant was made under but subject to stockholder approval of the Issuer's 2024 Omnibus Equity Incentive Plan and such grant at the Issuer's 2024 Annual Meeting. Such meeting was held, and such stockholder approval was obtained, on November 26, 2024. One-third shall vest and become exercisable in three installments on each of the first, second and third anniversaries of the date of grant through September 7, 2027.